Pharmacy firm eyes 2024 rollout of 1st targeted PET imaging agent for kidney cancer

2 years ago 55

Telix Pharmaceuticals recently submitted its license application to the FDA for the investigational positron emission tomography agent TLX250-CDx (Zircaix).

Read Entire Article

Pharmacy firm eyes 2024 rollout of 1st targeted PET imaging agent for kidney cancer

Related

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, ...

Study reveals potential new way to stop a common kidney canc...

Early prostate checkups needed to prevent kidney problems, c...

Trending

Popular

Darwin woman forced to fly interstate for a cancer diagnosis...

Reduce your risk of cancer: get involved and have fun

Stone Roses legend’s wife dead aged 52 after long cancer bat...

Former OU 2-sport standout Ryan Minor has no more treatment ...

B.C. woman raises awareness of pancreatic cancer after husba...